R
Richard B. Kim
Researcher at University of Western Ontario
Publications - 380
Citations - 33088
Richard B. Kim is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 89, co-authored 328 publications receiving 30436 citations. Previous affiliations of Richard B. Kim include London Health Sciences Centre & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.
Henriette E. Meyer zu Schwabedissen,Céline Verstuyft,Céline Verstuyft,Heyo K. Kroemer,Laurent Becquemont,Richard B. Kim,Richard B. Kim +6 more
TL;DR: It is shown that coordinate function of MATE1 with OCT2 likely contributes to the vectorial renal elimination of organic cationic drugs and that altered activity of Mate1, whether by drugs or polymorphisms, should be considered as an important determinant of renal cationIC drug elimination.
Journal ArticleDOI
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.
Mark T. Kinirons,Mark T. Kinirons,Mark T. Kinirons,Diarmuid O'Shea,Diarmuid O'Shea,Diarmuid O'Shea,Richard B. Kim,Richard B. Kim,Richard B. Kim,John D. Groopman,John D. Groopman,John D. Groopman,Kenneth E. Thummel,Kenneth E. Thummel,Kenneth E. Thummel,Alastair J. J. Wood,Alastair J. J. Wood,Alastair J. J. Wood,Grant R. Wilkinson,Grant R. Wilkinson,Grant R. Wilkinson +20 more
TL;DR: The purpose of this study was to investigate the relationship, if any, between the ERBT and midazolam's CYP3A‐mediated metabolism.
Journal ArticleDOI
Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug Development
TL;DR: The current and future applications of pharmacogenomics in clinical cancer therapy and cancer drug development are discussed.
Journal ArticleDOI
Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events
Richard B. Kim,Bridget L. Morse,Ognjenka Djurdjev,Mila Tang,Norman Muirhead,Brendan J. Barrett,Daniel T. Holmes,François Madore,Catherine M. Clase,Claudio Rigatto,Adeera Levin,Mohsen Agharazii,Joanne Blouin,Ayub Akbarii,Judy Cheesman,Jennilea Courtney,Sabrina Hamer,Edita Delic,Valerie Cronin,Paul E. Barre,Jeffrey Golden,Elizabeth Langille,Sandra Adams,Janet Morgan,Catherine M. Clase,Cathy Moreau,Susan Cooper,Brian R. Forzley,Susan Caron,Shauna Granger,Susan Valley,Helen Sather,Serge Cournoyer,Lorraine Menard,Michèle Roy,Hélène Skidmore,Dolores Beaudry,Janis Dionne,Josephine Chow,Valla Sahraei,Sandra Donnelly,Niki Dacouris,Rosa Marticorena,Brenda R. Hemmelgarn,Sharon Gulewich,Troy Hamilton,Paul Keown,Nadia Zalunardo,Daniel Rogers,Reena Tut,Matthew Paquette,Rossitta Yung,Nancy Ferguson,Helen H. L. Chiu,Kathleen Carlson,Lina Sioson,Taylor Perry,Zainab Sheriff,Naama Rozen,Charmaine Lok,Michelle Cross,Cathy Forrester,Alexandra Cotoi,Manon Maltais,Louise Moist,Kerri Gallo,Sarah Langford,Leah Slamen,Danielle Cram,Mary Jeanne Edgar,Taylor Gray,Cameron Edgar,Karen Groeneweg,Eileen McKinnon,Erin McRae,Kyla Blackie,Bharat Nathoo,Kimmy Lau,Malvinder S. Parmar,Sylvie Gelinas,Martine Leblanc,Lucie Lépine,Dolores Friesen,Steven D. Soroka,Susan Fleet,Jeanette Squires,Siva Thanamayooran,Michael Binder,Christine Hines,Brenda McNeil,Patrice McDougall,Joy Howard,Deborah Gillis,Kathleen Hines,Sheldon W. Tobe,Mary Chessman,Nancy Perkins,Martha Agelopoulos,Stacey Knox,Tiffany Richards,Marcello Tonelli,Susan Szigety,Dawn Opgenorth,Karen Yeates,Karen Mahoney +104 more
TL;DR: The results suggest that TMAO may represent a new potentially modifiable CV risk factor for CKD patients, and further studies are needed to determine sources of variability and if lowering of TmaO reduces CV risk in CKD.
Journal ArticleDOI
Overexpression of OATP1B3 confers apoptotic resistance in colon cancer.
Wooin Lee,Abbes Belkhiri,A. Craig Lockhart,Nipun B. Merchant,Hartmut Glaeser,Elizabeth Harris,M. Kay Washington,Elizabeth M. Brunt,Alexander Zaika,Richard B. Kim,Wael El-Rifai +10 more
TL;DR: The results suggest that OATP1B3 overexpression in colorectal cancer cells may provide a survival advantage by altering p53-dependent pathways by reducing the transcriptional activity of p53 and subsequent reductions in transcript and protein levels of its downstream transcription targets.